Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
Benzinga
Published Apr 02, 2024 16:39
Updated Apr 02, 2024 17:40
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
Benzinga - by Surbhi Jain, .
Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co‘s (NYSE:LLY) strategic positioning and technical resilience present a compelling investment opportunity.
Zepbound boasts impressive weight-loss efficacy in clinical trials. It also marks a significant milestone for Eli Lilly in the weight-loss drug market.
However, it’s imperative to note that competition remains stiff, with established players like Novo Nordisk A/S (NYSE:NVO), the maker of Ozempic, vying for market share.
Also Read: What Analysts Are Saying About Eli Lilly and Co Stock
Technical Setup – Moderately Bearish Sentiment/h2 Eli Lilly’s stock has performed well over the past year, gaining 116.84%. So far in 2024, the stock has returned 29.45% to investors.
Looking ahead, the current technical trend shows a moderate bearish sentiment with slight selling pressure observed. Despite this, there are signals indicating potential opportunities:
- Moving Averages: The 50-day and 200-day simple moving averages (SMAs) present a bullish signal, suggesting potential reversal in the near term. However, the shorter-term moving averages (8-day and 20-day) exhibit a sell signal, indicating a short-term bearish sentiment.
- Exponential Moving Averages (EMA): Similar to SMAs, EMAs reflect mixed signals, with shorter-term averages signaling bearish sentiments and longer-term averages indicating bullishness.
- MACD & RSI: The MACD indicator suggests a bullish market sentiment, underscoring potential bullish momentum. However, the RSI indicates that the stock is overbought, warranting cautious optimism.
- Bollinger Bands: Both short-term and long-term Bollinger Bands present a buy signal, suggesting a favorable risk-reward profile for investors.
Analyst Reaction: The most recent analyst ratings for Eli Lilly stock, released by Cantor Fitzgerald, Truist Securities, and JP Morgan on April 1, March 22 and March 15, respectively, contribute to an average price target of $838.33. This indicates a potential upside of 10.55% for Eli Lilly and Co based on the assessments of these three analysts.
LLY Price Action: Eli Lilly stock was trading at $758 a share at the time of publication.
Get The App
Read Next: Here’s How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
Image: Shutterstock
Latest Ratings for LLY
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | Mizuho | Maintains | Buy | |
| Jan 2022 | Morgan Stanley | Maintains | Overweight |
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.